ASCO 2023 Meeting Report — Lung Cancers

Highlights of the latest research.

The 2023 American Society of Clinical Oncology (ASCO) annual meeting, held June 2 to 6 in Chicago, highlighted important advances in treatment of lung and thoracic cancers. Here, Associate Editor Dr. Jyoti Patel reviews several key trials in non–small-cell lung cancer.

Adjuvant Osimertinib Improves 5-Year Overall Survival in EGFR -Mutated Non–Small-Cell Lung Cancer

Adjuvant treatment with osimertinib after resection of stage IB, II, or IIIA epidermal growth factor receptor (EGFR)–mutated non–small-cell lung cancer (NSCLC) significantly improves the chance of survival, regardless of whether patients received chemotherapy, according to the final overall survival (OS) analysis from the industry-sponsored, phase 3 ADAURA study (abstract LBA3 an…

Author

Jyoti D. Patel, MD, FASCO

Disclosures

Consultant/Advisory BoardTakeda; AstraZeneca; AnHeart; Lilly; AbbVie; Blueprint; Gilead; Sanofi; Daiichi Sankyo; Genentech

Jyoti D. Patel, MD, FASCO

Disclosures

Consultant/Advisory BoardTakeda; AstraZeneca; AnHeart; Lilly; AbbVie; Blueprint; Gilead; Sanofi; Daiichi Sankyo; Genentech

ASCO 2023 Meeting Report — Lung Cancers

Topics

Adjuvant Osimertinib Improves 5-Year Overall Survival in EGFR -Mutated Non–Small-Cell Lung Cancer

Author